Shams Sedigheh, Barazandeh Tehrani Maliheh, Civallero Gabriel, Minookherad Koosha, Giugliani Roberto, Setoodeh Aria, Haghi Ashtiani Mohammad Taghi
Children's Medical Center, Pediatrics Center of Excellence, Tehran University of Medical Sciences, Tehran, Iran.
Department of Pathology, Tehran University of Medical Sciences, Tehran, Iran.
J Diabetes Metab Disord. 2017 Sep 8;16:37. doi: 10.1186/s40200-017-0319-1. eCollection 2017.
Mucopolysaccharidosis type IVA, also known as Morquio A or MPS IV A, is an autosomal recessive disease caused by the deficiency of the lysosomal enzyme N-acetylgalactosamine-6-sulfate sulfatase (GALNS). The loss of GALNS activity leads to the impaired breakdown of glycosaminoglycans (GAGs) keratan sulfate and chondroitin-6-sulfate. The accumulation of GAGs results in multiple organ damage. The accurate and early diagnosis of this disorder helps enhance the effectiveness of the treatment. The present study uses a pre-designed protocol for testing GALNS activity in the leukocytes of Iranian patients with MPS IV A and their parents and compares it with healthy controls.
Patients with MPS IVA previously diagnosed through the measurement of enzyme activity or genetic analysis entered the study. Leukocytes were obtained from the heparinized blood of the participants. The GALNS activity was measured by a fluorometric method using 4-methylumbelliferyl-β-D-galactoside-6-sulfate (4MU-G6S) as the substrate and proper buffer solutions and calibrators.
The GALNS activity (nmol/17 h/mg protein) was reported as 0-7.4 in the MPSIV A patients, as 19.85-93.7 in their parents and as 38.4-164 in the healthy controls. Statistically significant differences were observed between the three groups in terms of enzyme activity. There were no significant differences in enzyme activity by age. The female subjects in both the patient and parents groups showed lower enzyme activity compared to the male subjects.
The fluorometric method was validated for the measurement of GALNS activity in leukocyte samples and identifying Iranian patients with MPS IV A.
IV型黏多糖贮积症A,也称为莫尔基奥A病或MPS IV A,是一种常染色体隐性疾病,由溶酶体酶N - 乙酰半乳糖胺 - 6 - 硫酸酯酶(GALNS)缺乏引起。GALNS活性丧失导致糖胺聚糖(GAGs)硫酸角质素和硫酸软骨素 - 6 - 硫酸酯的分解受损。GAGs的积累会导致多器官损伤。该疾病的准确早期诊断有助于提高治疗效果。本研究采用预先设计的方案检测伊朗MPS IV A患者及其父母白细胞中的GALNS活性,并与健康对照进行比较。
通过酶活性测定或基因分析先前诊断为MPS IV A的患者进入本研究。从参与者的肝素化血液中获取白细胞。使用4 - 甲基伞形酮基 - β - D - 半乳糖苷 - 6 - 硫酸酯(4MU - G6S)作为底物以及适当的缓冲溶液和校准剂,通过荧光法测量GALNS活性。
MPS IV A患者的GALNS活性(nmol/17小时/毫克蛋白质)报告为0 - 7.4,其父母为19.85 - 93.7,健康对照为38.4 - 164。三组之间在酶活性方面观察到统计学上的显著差异。酶活性在年龄方面无显著差异。患者组和父母组中的女性受试者与男性受试者相比,酶活性较低。
荧光法经验证可用于测量白细胞样本中的GALNS活性以及识别伊朗MPS IV A患者。